Table 7.
Adherence to OACs (PDC ≥80%) Within First 6 Months of Follow‐up, Stratified by Index Medication (N=64 661)
| Apixaban (n=3900) | Dabigatran (n=10 235) | Rivaroxaban (n=12 336) | All NOACs (n=26 471) | Warfarin (n=38 190) | P Value (All NOACs Pooled vs Warfarin) | |
|---|---|---|---|---|---|---|
| Unadjusted adherencea | ||||||
| All | 64.5% | 51.2% | 58.4% | 56.5% | 51.6% | <0.001 |
| CHA2DS2‐VASc score 0 or 1 | 53.2% | 37.1% | 45.8% | 42.6% | 40.3% | 0.06 |
| CHA2DS2‐VASc score 2 or 3 | 64.6% | 53.3% | 60.1% | 58.0% | 49.8% | <0.001 |
| CHA2DS2‐VASc score ≥4 | 66.7% | 55.0% | 61.0% | 59.8% | 53.4% | <0.001 |
| Adjusted adherence, 95% CIb | ||||||
| All | 62.5% (60.8–64.2) | 57.3% (56.2–58.4) | 59.5% (58.5–60.5) | 58.9% (58.2–59.7) | 49.9% (49.3–50.5) | <0.001 |
| CHA2DS2‐VASc score 0 or 1 | 51.2% (46.3–56.1) | 41.4% (39.0–43.7) | 44.4% (42.1–46.7) | 43.7% (42.1–45.2) | 37.8% (35.9–39.7) | <0.001 |
| CHA2DS2‐VASc score 2 or 3 | 62.4% (59.5–65.2) | 58.3% (56.6–60.0) | 60.1% (58.6–61.6) | 59.6% (58.5–60.6) | 48.3% (47.3–49.4) | <0.001 |
| CHA2DS2‐VASc score ≥4 | 64.4% (62.2–66.5) | 59.5% (58.0–61.0) | 61.7% (60.3–63.0) | 61.1% (60.2–62.1) | 52.8% (52.1–53.5) | <0.001 |
OAC, oral anticoagulant; PDC, proportion of days covered; NOAC, non–vitamin K antagonist oral anticoagulant; CHA 2 DS 2‐VASc, risk based on the presence of congestive heart failure, hypertension, age 65–74 y, age ≥75 y, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, sex category.
a
Unadjusted adherence was the percentage of patients with PDC ≥80%.
b
Adjusted adherence was the predicted probability of PDC ≥80% based on multivariable logistic regression.